Conmed (CNMD)

Conmed Income Statement


Conmed Income Statement

Last quarter (Q3 2022), Conmed's total revenue was $275.09M, an increase of 10.55% from the same quarter last year. In Q3, Conmed's net income was $46.15M. See Conmed’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
$ 1.07B$ 1.01B$ 862.46M$ 955.10M$ 859.63M$ 796.39M
Cost of Revenue
$ 473.34M$ 442.60M$ 402.16M$ 430.38M$ 390.52M$ 365.35M
Gross Profit
$ 595.24M$ 568.04M$ 460.30M$ 524.72M$ 469.11M$ 431.04M
Operating Expense
$ 486.87M$ 458.32M$ 414.29M$ 445.60M$ 397.81M$ 384.11M
Operating Income
$ 108.37M$ 109.72M$ 46.01M$ 79.11M$ 71.31M$ 46.94M
Net Non Operating Interest Income Expense
$ -27.03M$ -35.48M$ -44.05M$ -42.70M$ -20.65M$ -18.20M
Other Income Expense
$ -112.01M$ -1.13M$ -355.00K$ -5.19M--
Pretax Income
$ -30.68M$ 73.11M$ 1.60M$ 31.23M$ 50.65M$ 28.73M
Tax Provision
$ 52.05M$ 10.56M$ -7.91M$ 2.60M$ 9.80M$ -26.75M
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -82.72M$ 62.54M$ 9.52M$ 28.62M$ 40.85M$ 55.49M
Basic EPS
$ -2.80$ 2.14$ 0.33$ 1.01$ 1.45$ 1.99
Diluted EPS
$ -2.95$ 1.94$ 0.32$ 0.97$ 1.41$ 1.97
Basic Average Shares
$ 119.03M$ 29.16M$ 28.58M$ 28.32M$ 28.12M$ 27.94M
Diluted Average Shares
$ 128.84M$ 32.22M$ 29.46M$ 29.50M$ 28.89M$ 28.17M
Dividend Per Share
$ 0.80$ 0.80$ 0.80$ 0.80$ 0.80$ 0.80
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
$ 3.30$ 3.21$ 2.18$ 2.64$ 2.18$ 1.89
Rent Expense Supplemental
Total Expenses
$ 960.21M$ 900.92M$ 816.45M$ 875.98M$ 788.33M$ 749.46M
Net Income From Continuing And Discontinued Operation
$ -82.72M$ 62.54M$ 9.52M$ 28.62M$ 40.85M$ 55.49M
Normalized Income
$ -15.52M$ 62.54M$ 9.52M$ 28.62M$ 40.85M$ 55.49M
Interest Expense
$ 27.03M$ 35.48M$ 44.05M$ 42.70M$ 20.65M$ 18.20M
$ -3.65M$ 108.59M$ 45.66M$ 73.93M$ 71.31M$ 46.94M
$ 65.61M$ 179.33M$ 118.28M$ 146.25M$ 132.07M$ 104.44M
Currency in USD

Conmed Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis